Xtandi clinical trials
Xtandi is named as an intervention in 33 current clinical trials in our USA, China, Spain, Canada, South Korea, Australia, Italy, UK, France, Brazil, Japan, Poland, Germany, Taiwan, Netherlands, Sweden, Czechia, Turkey, Israel, Belgium, Austria, Denmark, Switzerland, Mexico, Norway, Singapore, Ireland, Portugal, Egypt and India registers. 15 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Pfizer (5). The most-studied condition is Prostate Cancer.
Patient leaflets for Xtandi
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Xtandi
33 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Xtandi
32 conditionsAll 32 conditions
| Condition (as registered) | Trials |
|---|---|
| Prostate Cancer | 6 |
| Metastatic Castration-Resistant Prostate Cancer | 3 |
| Metastatic Castration-resistant Prostate Cancer | 3 |
| Metastatic Castration-resistant Prostate Cancer (mCRPC) | 2 |
| Metastatic Prostate Cancer | 2 |
| Prostate Adenocarcinoma | 2 |
| Hormone Sensitive Prostate Cancer | 2 |
| Cancer of the Prostate | 2 |
| Prostatic Neoplasms, Castration-Resistant | 2 |
| Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | 2 |
| Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 2 |
| Prostatic Neoplasms | 1 |
| Prostate Cancer Metastatic | 1 |
| Metastatic Castration-Sensitive Prostate Cancer | 1 |
| Metastatic Castrate Resistant Prostate Cancer (mCRPC) | 1 |
| Metastatic Castration Sensitive Prostate Cancer (mCSPC) | 1 |
| mCRPC | 1 |
| Cancer | 1 |
| Metastatic Castration Resistant Prostate Cancer (mCRPC) | 1 |
| Small Cell Lung Cancer (SCLC) | 1 |
| Follicular Lymphoma (FL) | 1 |
| Metastatic Cancer | 1 |
| Neoplasm, Prostate | 1 |
| Castrate-sensitive | 1 |
| Castrate-sensitive Prostate Cancer | 1 |
| Metastatic Castration Resistant Prostate Cancer | 1 |
| Metastatic Hormone Sensitive Prostate Cancer | 1 |
| Metastatic Castrate-Resistant Prostate Cancer | 1 |
| mCRPC (Metastatic Castration-resistant Prostate Cancer) | 1 |
| Neoplasms | 1 |
| Castration-resistant Prostate Cancer Patients with Oligometastases | 1 |
| Castration-Resistant Prostate Cancer (CRPC) | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Pfizer | 5 |
| AstraZeneca | 4 |
| Merck Sharp & Dohme LLC | 2 |
| Zenith Epigenetics | 2 |
| Hoffmann-La Roche | 2 |
| Astellas Pharma Global Development, Inc | 1 |
| Exelixis | 1 |
| Syntrix Biosystems, Inc | 1 |
| Sun Pharmaceutical Industries Limited | 1 |
| ORIC Pharmaceuticals | 1 |
| Astellas (Beijing) Pharmaceutical R&D Co., Ltd | 1 |
| Evopoint Biosciences Inc | 1 |
| Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic | 1 |
| Leiden University Medical Center | 1 |
| Karolinska Institutet | 1 |
+ 8 more sponsors in the trial list above.
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Xtandi trials
How many clinical trials are testing Xtandi?
33 current trials in our USA, China, Spain, Canada, South Korea, Australia, Italy, UK, France, Brazil, Japan, Poland, Germany, Taiwan, Netherlands, Sweden, Czechia, Turkey, Israel, Belgium, Austria, Denmark, Switzerland, Mexico, Norway, Singapore, Ireland, Portugal, Egypt and India registers name Xtandi as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Xtandi trials recruiting patients?
Yes. 15 of the 33 trials are recruiting: 10 with sites in USA, 8 with sites in China, 7 with sites in Spain, 5 with sites in Canada, 6 with sites in South Korea, 5 with sites in Australia, 5 with sites in Italy, 5 with sites in UK, 5 with sites in France, 5 with sites in Brazil, 6 with sites in Japan, 5 with sites in Poland, 5 with sites in Germany, 5 with sites in Taiwan, 5 with sites in Netherlands, 5 with sites in Sweden, 4 with sites in Czechia, 5 with sites in Turkey, 4 with sites in Israel, 3 with sites in Belgium, 2 with sites in Austria, 2 with sites in Denmark, 4 with sites in Switzerland, 2 with sites in Mexico, 2 with sites in Norway, 2 with sites in Singapore, 2 with sites in Ireland, 1 with sites in Portugal, 2 with sites in Egypt and 1 with sites in India. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Xtandi clinical trials?
Pfizer (5), AstraZeneca (4), Merck Sharp & Dohme LLC (2) and Zenith Epigenetics (2), among 23 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Are there Xtandi clinical trials in Ireland?
Yes. 2 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Xtandi works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Xtandi works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Xtandi (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.